Mentor Corp. announced Wednesday that a drug it is developing in Madison to compete with the well-known and hugely successful Botox has successfully completed the first of three Phase 3 clinical trials.
Phase 3 is the final level of trials before a drug is submitted for U.S. Food and Drug Administration approval — assuming the trials produce successful results.
The Santa Barbara, Calif.-based company’s “PurTox” drug, which is derived from purified botulinum Type A neurotoxin, is designed to reduce frown lines.
….The development of PurTox stems from Mentor’s 2003 deal for an exclusive license from the Wisconsin Alumni Research Foundation for botulinum toxin technology developed at the University of Wisconsin-Madison.